The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pavlova T.G.

Kemerovo regional clinical dermatovenerologic dispensary, 650025, Kemerovo, Russia

Egoshina I.G.

State budgetary health care institution «Kemerovo Regional Clinical Dermatovenerologic Dispensary, Kemerovo, Russia

Experience in the use of secukinumab in a patient with severe palmoplantar psoriasis (in Russian only)

Authors:

Pavlova T.G., Egoshina I.G.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2018;17(5): 128‑133

DOI: 10.17116/klinderma201817051128

Read: 3165 times

Download PDF (RU)
Contact the author
Table of contents

EXPERIENCE IN THE USE OF SECUKINUMAB IN A PATIENT WITH SEVERE PALMOPLANTAR PSORIASIS (IN RUSSIAN ONLY)
EXPERIENCE IN THE USE OF SECUKINUMAB IN A PATIENT WITH SEVERE PALMOPLANTAR PSORIASIS (IN RUSSIAN ONLY)

To cite this article:

Pavlova TG, Egoshina IG. Experience in the use of secukinumab in a patient with severe palmoplantar psoriasis (in Russian only). Russian Journal of Clinical Dermatology and Venereology. 2018;17(5):128‑133. (In Russ.)
https://doi.org/10.17116/klinderma201817051128

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Chro­nic hidradenitis suppurativa: morbidity patterns and patients’ routing in Saint-Petersburg. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):255-260
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):453-460
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Abstract:

ABSTRACT Palmoplantar psoriasis holds a special place among all known clinical forms of psoriasis. It is known that this form of psoriasis is resistant to conventional treatments. Prolonged palmoplantar psoriasis forces patients to limit their professional, social, and sexual contacts, change their normal lifestyle; itching and painfulness complicates household and professional duties up to disability. The use of methotrexate, cyclosporine A, aromatic retinoids, and phototherapy in treatment of palmoplantar psoriasis does not provide pronounced persistent positive effect. The article presents current information on the treatment of this form of psoriasis using genetically engineered biological preparations. The data of the international clinical multicenter study GESTURE involving patients with palmoplantar psoriasis are reported. Selective effect of Secukinumab on inflammatory cytokines makes it not only effective, but also safe treatment. The article also reports clinical experience in the use of Secukinumab in treatment of a patient with severe palmoplantar psoriasis.

Keywords:

psoriasis
palmoplantar psoriasis
genetically engineered biological therapy
Secukinumab

Authors:

Pavlova T.G.

Kemerovo regional clinical dermatovenerologic dispensary, 650025, Kemerovo, Russia

Egoshina I.G.

State budgetary health care institution «Kemerovo Regional Clinical Dermatovenerologic Dispensary, Kemerovo, Russia

Close metadata

References:

  1. Dovzhanskiy SI, Pinson IYa. Genetic and immunological factors in the pathogenesis of psoriasis. Ros zhurn kozhn i venerich, bolezney. 2006;1:14-18. (In Russ.).
  2. Kubanova AA. Perspektivy razvitiya dermatovenerologicheskoj sluzhby v Rossijskoj Federatsii. Materialy raboty Pervogo Vserossijskogo kongressa dermatovenerologov. SPb., 2003. (In Russ.).
  3. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am AcadDermatol. 2014;70(3):512-516. https://doi.org/10.1037/e664712010-005
  4. Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. Dermatovenereology in the Russian Federation. Results of 2014. Successes, achievements. The main ways of development. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2015;4:109-115. (In Russ.).
  5. Serebryakova IS. Kliniko laboratornaya diagnostika ladonno-podoshvennyh form psoriaza v sochetanii s urogenitalnymi infekciyami:. Dis... kand. med. nauk. SPb. 2013. (In Russ.).
  6. Perminova MA. Primenenie ultrafonoforeza kombinirovannogo preparata s kalcipotriolom u bolnyh ladonno-podoshvennym psoriazom: Diss... kand. med. nauk. M. 2012. (In Russ.).
  7. Dauden E, Castaneda S, Suarez C, Garcıa-Campayo J, Blasco AJ, Aguilar MD, Ferrandiz C, Puig L, Sanchez-Carazo JL. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. 2015.
  8. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509. 16. https://doi.org/10.1056/nejmra0804595
  9. Bakulev AL. The strategy of «treatment before the goal» in psoriasis. Topical issues of resistance to biological therapy. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2016;(5):32-38. (In Russ.).
  10. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490-500. https://doi.org/10.4049/jimmunol.1100123
  11. Dannye predostavleny kompaniej Novartis. Arhiv foto pacientov iz issledovaniya TRANSFIGURE (CAIN457A2313) (In Russ.).
  12. Langley R, et al. Efficacy of response and safety of two fixed secukinumab regimens in psoriasis. N Engl J Med. 2014;371:326-338.
  13. Mrowietz U, et al. Secukinumabretretment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73:27-36.
  14. Thaçi D, Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-409.
  15. Bagel J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77:667-674.
  16. Blauvelt A, et al. Br J Dermatol. 2015;172:484-493.
  17. Gottlieb A, et al. Results of the FEATURE trial. J Drugs Dermatol. 2016;15(10):1226-1234.
  18. Gottlieb A, et al. Secukinumab shows significantefficacy in palmoplantar psoriasis: Resultsfrom GESTURE, a randomizedcontrolled trial. J Am Acad Dermatol. 2017;76:70-80.
  19. Korotayeva TV. Prospects for the use of interleukin-17 inhibitors — a new class of drugs for targeted therapy of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2016;54(3). (In Russ.).
  20. Strober B, Gottlieb A, Sherif B, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017;76:655-661. https://doi.org/10.1016/j.jaad.2016.11.043
  21. Kungurov NV, Zilberberg NV, Kokhan MM, Keniksfest YuV, Grishaeva EV. Experience of the use of the drug secukinumab therapy of severe resistant psoriasis. Leash doctor 2017 november;11:1-6. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.